Table 1 Characteristics of included articles
Study | Country (Region) | SRs/MAs | Whether CDSR | Type of SRs | Type of included studies | Preregistration | PRISMA | Funding | Disease | Sample size |
|---|---|---|---|---|---|---|---|---|---|---|
Collins et al. 1999 [33] | USA (North America) | SRs | CDSR | Interventional | RCT/Crossover trail/CCT | Y | N | Y | CP/CPPS (III) | 600 |
Collins et al. 2000 [34] | USA (North America) | SRs | Non-CDSR | Interventional | RCT/Crossover trail/CCT | N | N | Y | CP/CPPS | 1954 |
Collins et al. 2002 [35] | USA (North America) | SRs | CDSR | Interventional | RCT | Y | N | Y | CP/CPPS (IIIA/IIIB) | 54 |
Yang et al. 2006 [36] | China (Asia) | MAs | Non-CDSR | Interventional | RCT | N | N | N | CP/CPPS (III) | 734 |
Lee et al. 2007 [37] | USA (North America) | SRs | Non-CDSR | Interventional | open-label or small prospective studies/ double-blinded and placebo-controlled clinical trials | N | N | N | CP/CPPS | 818 |
Mishra et al. 2007 [38] | UK (Europe) | SRs | Non-CDSR | Interventional | RCT | N | N | N | CP/CPPS (III) | 386 |
Yang et al. 2008 [39] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | N | N | N | CP/CPPS | 1050 |
Anothaisintawee et al. 2011 [40] | Thailand (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | N | N | Y | CP/CPPS (IIIA/IIIB) | 2021 |
Aboumarzouk et al. 2012 [41] | UK (Europe) | SRs | CDSR | Interventional | RCT | Y | N | Y | CP/CPPS (IIIA/IIIB) | 324 |
Cohen et al. 2012 [42] | USA (North America) | SRs/MAs | Non-CDSR | Interventional | RCT | N | Y | N | CP/CPPS (III) | 3312 |
Thakkinstian et al. 2012 [43] | Canada (North America) | SRs/MAs | Non-CDSR | Interventional | RCT | N | N | N | CP/CPPS (IIIA/IIIB) | 1669 |
Moldwin et al. 2013 [44] | USA (North America) | SRs | Non-CDSR | Interventional | RCT/NRSI | N | N | N | CP/CPPS | NR |
Fu et al. 2014 [45] | China (Asia) | SRs/MAs | Non-CDSR | Non-interventional | case–control studies | N | Y | N | CP/CPPS | 1454 |
Riegel et al. 2014 [46] | Germany (Europe) | SRs | Non-CDSR | Non-interventional | RCT/prospective study/Retrospective review/Case–control study/Experimental study/Evaluation of clinical data/Longitudinal study/cohort study | Y | Y | Y | CP/CPPS (IIIA/IIIB) | 44,650 |
Zhu et al. 2014 [47] | China (Asia) | MAs | Non-CDSR | Interventional | RCT | N | N | N | CP/CPPS (III) | 539 |
Chen et al. 2015 [48] | China (Asia) | SRs/MAs | Non-CDSR | Non-interventional | Case–control studies/cohort studies/cross-sectional studies | Y | Y | N | CP/CPPS | 33,033 |
Li et al. 2015 [49] | China (Asia) | MAs | Non-CDSR | Non-interventional | Observational studies/cohort studies/cross-sectional studies/case series | N | N | N | CP/CPPS | 11,189 |
Liu et al. 2016 [50] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | N | Y | N | CP/CPPS | 754 |
Qin et al. 2016a [51] | China (Asia) | MAs | Non-CDSR | Interventional | RCT | N | Y | N | CP/CPPS (III) | 1203 |
Qin et al. 2016b [52] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | Y | Y | N | CP/CPPS (III) | 471 |
Cai et al. 2017 [53] | Italy (Europe) | SRs/MAs | Non-CDSR | Interventional | pre-clinical studies/clinical trials/RCT/cohort studies/case–control studies | N | Y | N | CP/CPPS | 590 |
Chang et al. 2017 [54] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | N | Y | Y | CP/CPPS (IIIA/IIIB) | 502 |
Anderson et al. 2018 [55] | USA (North America) | MAs | Non-CDSR | Interventional | RCT/case series | N | Y | N | CP/CPPS | 380 |
Franco et al. 2018 [56] | Argentina (South America) | SRs/MAs | CDSR | Interventional | RCT | Y | Y | N | CP/CPPS (III) | 3290 |
Franco et al. 2019 [57] | Argentina (South America) | SRs/MAs | CDSR | Interventional | RCT | Y | Y | N | CP/CPPS (III) | 9119 |
Liao et al. 2019 [58] | China (Asia) | MAs | Non-CDSR | Interventional | RCT | N | N | Y | CP/CPPS | 838 |
Qin et al. 2019a [59] | China (Asia) | MAs | Non-CDSR | Interventional | RCT/case series | N | Y | Y | CP/CPPS | 329 |
Qin et al. 2019b [60] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT/case series | N | Y | Y | CP/CPPS | 439 |
Yuan et al. 2019 [61] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | N | N | Y | CP/CPPS | 280 |
Birowo et al. 2020 [62] | Indonesia (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | Y | Y | Y | CP/CPPS | 137 |
Huang et al. 2020 [63] | China (Asia) | MAs | Non-CDSR | Non-interventional | cross-sectional studies | N | Y | Y | CP/CPPS | 1308 |
Li et al. 2020 [64] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | N | Y | Y | CP/CPPS (III) | 748 |
Chen et al. 2021 [65] | China (Asia) | SRs/MAs | Non-CDSR | Non-interventional | RCT/NRSI | N | Y | Y | CP/CPPS | NR |
Kang et al. 2021 [66] | China (Asia) | MAs | Non-CDSR | Interventional | RCT | N | Y | Y | CP/CPPS | 525 |
Li et al. 2021 [67] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT/Non-RCT | N | Y | Y | CPPS | 317 |
Mykoniatis et al. 2021 [68] | Greece (Europe) | SRs/MAs | Non-CDSR | Interventional | RCT | Y | Y | N | CP/CPPS (IIIB) | 316 |
Zhang et al. 2021a [69] | China (Asia) | MAs | Non-CDSR | Interventional | RCT | N | Y | Y | CP/CPPS (IIIA/IIIB) | 770 |
Zhang et al. 2021b [70] | China (Asia) | MAs | Non-CDSR | Interventional | RCT | Y | Y | Y | CP/CPPS with SD | 2996 |
Kong et al. 2022 [71] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | Y | Y | Y | CP/CPPS | 651 |
Lao et al. 2022 [72] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | Y | Y | Y | CP/CPPS (IIIA/IIIB) | 4244 |
Lok et al. 2022 [73] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | N | Y | N | CP/CPPS | 434 |
Andrey et al. 2022 [6] | Russia (Europe) | SRs/MAs | Non-CDSR | Interventional | RCT | Y | Y | N | CP/CPPS | 5512 |
Qin et al. 2022a [7] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | Y | Y | Y | CP/CPPS | 1188 |
Qin et al. 2022b [74] | China (Asia) | SRs/MAs | Non-CDSR | Interventional | RCT | Y | Y | Y | CP/CPPS | 3514 |
Zhao et al. 2022 [75] | China (Asia) | SRs | Non-CDSR | Non-interventional | RCT/Non-RCT | N | Y | Y | CP/CPPS (III) | 431 |